source
- GSK to acquire Chimagen’s trispecific T-cell engager program in deal up to $750 millionGSK announced it will acquire a preclinical trispecific T cell engager program from Chinese biotech Chimagen Biosciences in a transaction that could total up to $750 million. The agreement provide…
- FDA launches Operation TrialBlazer to accelerate early-stage drug trials and bring research back to the U.S.The FDA announced it is now accepting applications for Operation TrialBlazer, an expedited IND pilot program. The program pairs drug sponsors with qualified U.S. research institutions to cut the r…